Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 6 , Pages 730-737 , December 2010

New metal-based nanoparticles for intravenous use: requirements for clinical success with focus on medical imaging

  • Tore Skotland, PhD

      Affiliations

    • Centre for Cancer Biomedicine, Faculty Division Norwegian Radium Hospital, University of Oslo, Oslo, Norway
    • Department of Biochemistry, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
    • Corresponding Author InformationCorresponding author: Department of Biochemistry, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Montebello, 0310 Oslo, Norway.
    • ,
  • Tore-Geir Iversen, PhD

      Affiliations

    • Centre for Cancer Biomedicine, Faculty Division Norwegian Radium Hospital, University of Oslo, Oslo, Norway
    • Department of Biochemistry, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
    • ,
  • Kirsten Sandvig, PhD

      Affiliations

    • Centre for Cancer Biomedicine, Faculty Division Norwegian Radium Hospital, University of Oslo, Oslo, Norway
    • Department of Biochemistry, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
    • Department of Molecular Biosciences, University of Oslo, Oslo, Norway

Received 4 February 2010 ,Accepted 7 May 2010.

References 

  1. Hoffman JM, Gambhir SS. Molecular imaging: the vision and opportunity for radiology in the future. Radiology. 2007;244:39–47
  2. McCarthy JR, Kelly KA, Sun EY, Weissleder R. Targeted delivery of multifunctional magnetic nanoparticles. Nanomedicine (Lond.). 2007;2:153–167
  3. Kaufmann BA, Lindner JR. Molecular imaging with targeted contrast ultrasound. Curr Opin Biotechnol. 2007;18:11–16
  4. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature. 2008;452:580–589
  5. Wadsak W, Mitterhauser M. Basics and principles of radiopharmaceuticals for PET/CT. Eur J Radiol. 2010;73:461–469
  6. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003;17:545–580
  7. Corot C, Robert P, Idee JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev. 2006;58:1471–1504
  8. Gao X, Yang L, Petros JA, Marshall FF, Simons JW, Nie S. In vivo molecular and cellular imaging with quantum dots. Curr Opin Biotechnol. 2005;16:63–72
  9. Jamieson T, Bakhshi R, Petrova D, Pocock R, Imani M, Seifalian AM. Biological applications of quantum dots. Biomaterials. 2007;28:4717–4732
  10. Michalet X, Pinaud FF, Bentolila LA, Tsay JM, Doose S, Li JJ, et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science. 2005;307:538–544
  11. Pan D, Lanza GM, Wickline SA, Caruthers SD. Nanomedicine: perspective and promises with ligand-directed molecular imaging. Eur J Radiol. 2009;70:274–285
  12. Devaraj NK, Keliher EJ, Thurber GM, Nahrendorf M, Weissleder R. 18F-labeled nanoparticles for in vivo PET-CT imaging. Bioconjug Chem. 2009;20:397–401
  13. Cormode DP, Jarzyna PA, Mulder WJ, Fayad ZA. Modified natural nanoparticles as contrast agents for medical imaging. Adv Drug Deliv Rev. 2010;62:329–338
  14. Nyk M, Kumar R, Ohulchanskyy TY, Bergey EJ, Prasad PN. High contrast in vitro and in vivo photoluminescence bioimaging using near infrared to near infrared up-conversion in Tm3+ and Yb3+ doped fluoride nanophosphors. Nano Lett. 2008;8:3834–3838
  15. Li Z, Zhang Y, Shuter B, Muhammad IN. Hybrid lanthanide nanoparticles with paramagnetic shell coated on upconversion fluorescent nanocrystals. Langmuir. 2009;25:12015–12018
  16. Burns AA, Vider J, Ow H, Herz E, Penate-Medina O, Baumgart M, et al. Fluorescent silica nanoparticles with efficient urinary excretion for nanomedicine. Nano Lett. 2009;9:442–448
  17. Hainfeld JF, Slatkin DN, Focella TM, Smilowitz HM. Gold nanoparticles: a new X-ray contrast agent. Br J Radiol. 2006;79:248–253
  18. Patra CR, bdel Moneim SS, Wang E, Dutta S, Patra S, Eshed M, et al. In vivo toxicity studies of europium hydroxide nanorods in mice. Toxicol Appl Pharmacol. 2009;240:88–98
  19. Gilad AA, Walczak P, McMahon MT, Na HB, Lee JH, An K, et al. MR tracking of transplanted cells with "positive contrast" using manganese oxide nanoparticles. Magn Reson Med. 2008;60:1–7
  20. Maysinger D, Lovric J, Eisenberg A, Savic R. Fate of micelles and quantum dots in cells. Eur J Pharm Biopharm. 2007;65:270–281
  21. Hild WA, Breunig M, Goepferich A. Quantum dots—nano-sized probes for the exploration of cellular and intracellular targeting. Eur J Pharm Biopharm. 2008;68:153–168
  22. Zhang H, Yee D, Wang C. Quantum dots for cancer diagnosis and therapy: biological and clinical perspectives. Nanomedicine (Lond.). 2008;3:83–91
  23. Juzenas P, Chen W, Sun YP, Coelho MA, Generalov R, Generalova N, et al. Quantum dots and nanoparticles for photodynamic and radiation therapies of cancer. Adv Drug Deliv Rev. 2008;60:1600–1614
  24. Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond.). 2008;3:703–717
  25. Delehanty JB, Mattoussi H, Medintz IL. Delivering quantum dots into cells: strategies, progress and remaining issues. Anal Bioanal Chem. 2009;393:1091–1105
  26. Patra CR, Bhattacharya R, Mukhopadhyay D, Mukherjee P. Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev. 2010;62:346–361
  27. Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm. 2008;69:1–9
  28. Nel A, Xia T, Madler L, Li N. Toxic potential of materials at the nanolevel. Science. 2006;311:622–627
  29. Klaine SJ, Alvarez PJ, Batley GE, Fernandes TF, Handy RD, Lyon DY, et al. Nanomaterials in the environment: behavior, fate, bioavailability, and effects. Environ Toxicol Chem. 2008;27:1825–1851
  30. Xia T, Li N, Nel AE. Potential health impact of nanoparticles. Annu Rev Public Health. 2009;30:137–150
  31. Rzigalinski BA, Strobl JS. Cadmium-containing nanoparticles: perspectives on pharmacology and toxicology of quantum dots. Toxicol Appl Pharmacol. 2009;238:280–288
  32. Jones CF, Grainger DW. In vitro assessments of nanomaterial toxicity. Adv Drug Deliv Rev. 2009;61:438–456
  33. Derfus AM, Chan WCW, Bhatia SN. Probing the cytotoxicity of semiconductor quantum dots. Nano Lett. 2004;4:11–18
  34. Cho SJ, Maysinger D, Jain M, Roder B, Hackbarth S, Winnik FM. Long-term exposure to CdTe quantum dots causes functional impairments in live cells. Langmuir. 2007;23:1974–1980
  35. Schneider GF, Subr V, Ulbrich K, Decher G. Multifunctional cytotoxic stealth nanoparticles. A model approach with potential for cancer therapy. Nano Lett. 2009;9:636–642
  36. Choi HS, Ipe BI, Misra P, Lee JH, Bawendi MG, Frangioni JV. Tissue- and organ-selective biodistribution of NIR fluorescent quantum dots. Nano Lett. 2009;9:2354–2359
  37. Schipper ML, Iyer G, Koh AL, Cheng Z, Ebenstein Y, Aharoni A, et al. Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small. 2009;5:126–134
  38. Aillon KL, Xie Y, El-Gendy N, Berkland CJ, Forrest ML. Effects of nanomaterial physicochemical properties on in vivo toxicity. Adv Drug Deliv Rev. 2009;61:457–466
  39. Hauck TS, Anderson RE, Fischer HC, Newbigging S, Chan WCW. In vivo quantum-dot toxicity assessment. Small. 2010;6:138–144
  40. Sonavane G, Tomoda K, Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf B Biointerfaces. 2008;66:274–280
  41. De Jong WH, Hagens WI, Krystek P, Burger MC, Sips AJ, Geertsma RE. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials. 2008;29:1912–1919
  42. Braet F, Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol. 2002;1:1
  43. Jarad G, Miner JH. Update on the glomerular filtration barrier. Curr Opin Nephrol. Hypertens. 2009;18:226–232
  44. Goldberg BB, Merton DA, Liu JB, Murphy G, Forsberg F. Contrast-enhanced sonographic imaging of lymphatic channels and sentinel lymph nodes. J Ultrasound Med. 2005;24:953–965
  45. Hoshino A, Hanaki K, Suzuki K, Yamamoto K. Applications of T-lymphoma labeled with fluorescent quantum dots to cell tracing markers in mouse body. Biochem Biophys Res Commun. 2004;314:46–53
  46. Ballou B, Lagerholm BC, Ernst LA, Bruchez MP, Waggoner AS. Noninvasive imaging of quantum dots in mice. Bioconjug Chem. 2004;15:79–86
  47. Moestue S, Nunez P, Healey A, Bjerke R, Indrevoll B, Skotland T, et al. Whole-body section fluorescence imaging—a novel method for tissue distribution studies of fluorescent substances. Contrast Media Mol Imaging. 2009;4:73–80
  48. Yang RSH, Chang LW, Wu JP, Tsai MH, Wang HJ, Kuo YC, et al. Persistent tissue kinetics and redistribution of nanoparticles, quantum dot 705, in mice: ICP-MS quantitative assessment. Environ Health Perspect. 2007;115:1339–1343
  49. Sadauskas E, Danscher G, Stoltenberg M, Vogel U, Larsen A, Wallin H. Protracted elimination of gold nanoparticles from mouse liver. Nanomed Nanotechnol Biol Med. 2009;5:162–169
  50. Steinman RM, Mellman IS, Muller WA, Cohn ZA. Endocytosis and the recycling of plasma membrane. J Cell Biol. 1983;96:1–27
  51. Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Itty IB, et al. Renal clearance of quantum dots. Nat Biotechnol. 2007;25:1165–1170
  52. Balogh L, Nigavekar SS, Nair BM, Lesniak W, Zhang C, Sung LY, et al. Significant effect of size on the in vivo biodistribution of gold composite nanodevices in mouse tumor models. Nanomed Nanotechnol Biol Med. 2007;3:281–296
  53. Schipper ML, Cheng Z, Lee SW, Bentolila LA, Iyer G. Rao J, et al. microPET-based biodistribution of quantum dots in living mice. J Nucl Med. 2007;48:1511–1518
  54. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol. 2001;11:2319–2331
  55. Rogers WJ, Meyer CH, Kramer CM. Technology insight: in vivo cell tracking by use of MRI. Nat Clin Pract Cardiovasc Med. 2006;3:554–562
  56. Skotland T, Sontum PC, Oulie I. In vitro stability analyses as a model for metabolism of ferromagnetic particles (Clariscan), a contrast agent for magnetic resonance imaging. J Pharm Biomed Anal. 2002;28:323–329
  57. Trikha J, Waldo GS, Lewandowski FA, Ha Y, Theil EC, Weber PC, et al. Crystallization and structural analysis of bullfrog red cell L-subunit ferritins. Proteins. 1994;18:107–118
  58. Hardman RA. A toxicological review of quantum dots: toxicity depends on physiochemical and environmental factors. Environ Health Perspect. 2006;114:165–172
  59. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) . Guidance for industry. Developing medical imaging drug and biological products. Part 1: Conducting safety assessments. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidance/ucm078930.pdf2004;
  60. http://las.perkinelmer.com/Content/TechnicalInfo/TCH_ICPMSThirtyMinuteGuide.pdf.
  61. Tysiak E, Asbach P, Aktas O, Waiczies H, Smyth M, Schnorr J, et al. Beyond blood brain barrier breakdown—in vivo detection of occult neuroinflammatory foci by magnetic nanoparticles in high field MRI. J Neuroinflammation. 2009;6:20
  62. Laurent S, Vander EL, Muller RN. Lanthanide complexes for magnetic resonance and optical molecular imaging. Q J Nucl Med Mol Imaging. 2009;53:586–603
  63. Rabin O, Manuel PJ, Grimm J, Wojtkiewicz G, Weissleder R. An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nat Mater. 2006;5:118–122
  64. Rofsky NM, Sherry AD, Lenkinski RE. Nephrogenic systemic fibrosis: a chemical perspective. Radiology. 2008;247:608–612
  65. Zolnik BS, Sadrieh N. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs. Adv Drug Deliv Rev. 2009;61:422–427

 No conflict of interest was reported by the authors of this article.

PII: S1549-9634(10)00157-7

doi: 10.1016/j.nano.2010.05.002

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 6 , Pages 730-737 , December 2010

Article Tools

* Image Usage & Resolution